Business Context and Reporting Period
This Form 8-K is a current report filed by Oncocyte Corporation (trading symbol: OCX) on June 17, 2024. The filing discloses the appointment of a new Chief Financial Officer and details the associated compensatory arrangements. Note: The request metadata references "Insight Molecular Diagnostics Inc.," but the filing text explicitly identifies the registrant as Oncocyte Corporation.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and corporate governance.
Material Changes
The primary material change reported is the appointment of Andrea James as Chief Financial Officer and Principal Financial Officer, effective June 17, 2024. James Liu will continue to serve as Senior Director, Controller, and Principal Accounting Officer.
Guidance, Outlook, and Compensation Details
The filing details the employment agreement and equity grants for the new CFO:
- Base Salary: $325,000 annually.
- Annual Bonus: Targeted at 50% of the Base Salary.
- Equity Grants:
- Stock Option Grant: 200,000 shares of Common Stock.
- Performance Equity Grant: 100,000 Restricted Stock Units (RSUs).
- Termination Provisions: In the event of termination without Cause or resignation with Good Reason, the agreement provides for 12 months of Base Salary, pro-rated bonus, health premium reimbursement for up to 12 months, and accelerated vesting of certain equity awards.
- Conditions: The equity grants are subject to shareholder approval of an amendment to the Company's 2018 Equity Incentive Plan.
Investor Verification Checklist
- Verify the shareholder approval status of the amendment to the 2018 Equity Incentive Plan required for the new CFO's equity grants.
- Review the full text of the Employment Agreement attached as an exhibit to the Form 10-Q for the period ending June 30, 2024.
- Confirm the transition timeline for James Liu's role as Principal Accounting Officer.
- Check for any subsequent filings regarding the outcome of the shareholder vote on the equity plan amendment.